December 15, 2021
Idera Pharmaceuticals Announces Tilsotolimod Updates
EXTON, Pa., Dec. 14, 2021 (GLOBE NEWSWIRE) — Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” and “our”) (Nasdaq: IDRA)…
Pharmaceuticals, Biotechnology and Life Sciences
EXTON, Pa., Dec. 14, 2021 (GLOBE NEWSWIRE) — Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” and “our”) (Nasdaq: IDRA)…
Responding to the rapidly evolving SARS-CoV-2, emerging variants and changing treatment landscape, Atea is updating the development strategy for AT-527…
NEW YORK, Dec. 13, 2021 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory…
– Additional Data Presented at ASH Support the Potential of Mitapivat to Improve Ineffective Erythropoiesis and Iron Overload and Stabilize…
Oral poster highlights data from 14 heavily pre-treated patients enrolled in pilot stage of multicenter, open-label, single arm CHARIOT study…
Promising execution in the clinic with programs in hemophilia B, Fabry disease and Gaucher disease; potential to deliver transformative therapies…
– Company plans to prioritize MPS-1 and diabetes with continued focus on platform optimization – – Workforce reduction of approximately…
5 of 6 Patients Achieve Objective Response, including 4 Patients with Complete Response, with Single Dose of FT596 at 900…
HM43239 Data Featured in Oral Presentation at the American Society of Hematology Annual Meeting Aptose Presents Highlights from Luxeptinib and APTO-253…
Not for distribution by US newswire or in United StatesNESS-ZIONA, Israel, Dec. 13, 2021 (GLOBE NEWSWIRE) — VAXIL BIO LTD.…